Movano completes blood pressure study with 110 participants

Pleasanton, calif. , jan. 3, 2022 /prnewswire/ -- movano inc. (nasdaq:move), a health technology company designing devices that inspire and empower you to live a healthier, happier life, today announced the completion of an institutional review board (irb)-approved blood pressure clinical study, which was conducted on 110 consented participants at the movano clinical lab over a six week period in the fourth quarter of 2021.
MOVE Ratings Summary
MOVE Quant Ranking